Supernus Pharmaceuticals, Inc. (SUPN) Earnings History
Profitable18 years of earnings data (2008–2025) · Positive TTM net income
Loading earnings history...
Supernus Pharmaceuticals, Inc. (SUPN) Earnings Overview
As of November 18, 2026, Supernus Pharmaceuticals, Inc. (SUPN) reported trailing twelve-month net income of $450M, reflecting +10833.3% year-over-year growth. The company earned $3.69 per diluted share over the past four quarters, with a net profit margin of 16.9%.
Looking at the long-term picture, SUPN's historical earnings data spans multiple years. The company achieved its highest annual net income of $263M in fiscal 2018.
Supernus Pharmaceuticals, Inc. maintains industry-leading profitability with a gross margin of 80.1%, operating margin of 21.4%, and net margin of 16.9%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including PCRX ($38M net income, 1.0% margin), ACAD ($362M net income, 36.5% margin), INVA ($193M net income, 63.8% margin), SUPN has outperformed on profitability metrics. Compare SUPN vs PCRX →
SUPN Earnings vs Peers
Earnings metrics vs comparable public companies
SUPN Historical Earnings Data (2008–2025)
18 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $210M | +10400.0% | $265M | $1.64 | 16.9% | 21.4% |
| 2024 | $2M | +101.6% | $32M | $0.01 | 0.2% | 2.7% |
| 2023 | -$129M | -193.2% | -$156M | $-0.91 | -11.8% | -14.3% |
| 2022 | -$44M | -121.5% | -$81M | $-0.37 | -4.9% | -9.0% |
| 2021 | $205M | +238.5% | $213M | $1.31 | 25.9% | 26.9% |
| 2020 | -$148M | -210.4% | -$156M | $-1.08 | -22.9% | -24.1% |
| 2019 | $134M | -49.0% | $178M | $0.92 | 17.1% | 22.7% |
| 2018 | $263M | +331.1% | $317M | $1.75 | 27.4% | 33.0% |
| 2017 | $61M | +90.1% | $423M | $0.41 | 5.3% | 36.9% |
| 2016 | $32M | +128.7% | $338M | $0.22 | 3.3% | 34.9% |
| 2015 | $14M | -29.5% | $18M | $0.28 | 9.7% | 12.2% |
| 2014 | $20M | +121.5% | $24M | $0.32 | 16.3% | 19.9% |
| 2013 | -$92M | -99.4% | -$62M | $-2.90 | -767.7% | -515.2% |
| 2012 | -$46M | -182.6% | -$42M | $-2.65 | -3127.3% | -2849.3% |
| 2011 | $56M | +245.6% | -$38M | $3.64 | 6974.2% | -4701.4% |
| 2010 | -$38M | -8461.5% | -$40M | $-2.78 | -36285.8% | -37851.9% |
| 2009 | $460,000 | +101.4% | $4M | $-0.21 | 1.2% | 10.6% |
| 2008 | -$33M | - | -$26M | $-2.42 | -376.7% | -290.9% |
Download Data
Export SUPN earnings history in CSV or JSON format
Free sign-in required to download data
SUPN Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
18+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SUPN — Frequently Asked Questions
Quick answers to the most common questions about buying SUPN stock.
What is SUPN earnings per share (EPS)?
SUPN trailing twelve-month (TTM) diluted EPS is $3.69, reflecting +10833.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2008 to 2025 is available in the table on this page.
What is Supernus Pharmaceuticals, Inc.'s net income?
Supernus Pharmaceuticals, Inc. (SUPN) trailing twelve-month net income is $450M as of 2025. Earnings grew +10833.3% year-over-year. Supernus Pharmaceuticals, Inc. has been profitable for 2 consecutive years.
Is SUPN profitable?
Yes, SUPN is profitable with a TTM net income of $450M and a net profit margin of +16.9%. Supernus Pharmaceuticals, Inc. has generated profits for 2 consecutive years.
What is SUPN's earnings growth rate?
SUPN compound annual EPS growth rates (CAGR): 1-Year: +10833.3%, 3-Year: N/A, 5-Year: N/A, 10-Year: +19.3%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2008 to 2025.
What are SUPN's profit margins?
Supernus Pharmaceuticals, Inc. net profit margin is +16.9%, operating margin is +21.4%, and gross margin is +80.1%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is N/A.
Is SUPN growing earnings?
Yes, SUPN earnings are accelerating — EPS growth of +10833.3% exceeds the 5-year CAGR of N/A. TTM net income reached $450M. Earnings momentum is strengthening.
What was SUPN's best earnings year?
Supernus Pharmaceuticals, Inc.'s highest annual net income on record is $263M, achieved in fiscal year 2018. Earnings history on this page spans 2008 to 2025 and includes all annual and quarterly figures.
What were SUPN's earnings last quarter?
SUPN's most recent reported quarter was Q3 2026. Net income was $137M with diluted EPS of $1.12. For a full breakdown of all quarters, see the quarterly earnings table on this page.